CK
Ceryvyn Therapeutics Limited
CKDXF · OTC
$0.01 +0.00% (+$0.00)
Market Cap $13.7M
P/E Ratio 0.06x
Div. Yield -
ROE -
Bulios Fair Price
$0.02
100.0% upside
Current Price
$0.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CKDXF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
75 /100
Cheap P/E 0.06x
P/S 19,797.10x
P/B 0.67x
Growth
0 /100
Declining Rev. growth 81.44%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 0.00%
Net margin 33,082,300.00%
Op. margin 1,196,070.00%
Quality
21 /100
Poor ROIC 40.37%
ROA 1,034.84%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.00x
Current ratio 13.78x
Int. coverage -1.08x
Stability
11 /100
Unstable Beta 1.51x
Rev. volatility 60.63%
EPS volatility 110.56%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CKDXF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeremy Max Levin Ba Zoology Dphil Mb Bchir
Employees
33
Headquarters
Melbourne
Upcoming events
23 FEB
Earnings
Upcoming earnings report